PRELIMINARY LIST OF TOPICS

• Amyloidosis
• Presenilin
• Potential Disease Modification in AD (Alpha-, Beta- & Gamma- Secretases and Prevention of A-Beta Aggregation)
  
• Treatment and Potential Disease Modification in AD (Amyloid Modulation via Cholinergic & Related Therapies)
• AChE Inhibition: Basic & Therapeutic Aspects
• Beta-Amyloid Modulation (via Cholesterol, ApoE Pathways, Signal Transduction)
• Disease Modification in AD (Beta Amyloid Modulation: The Immune and "Sink" Approach)
• Low Molecular Weight Glycosaminoglycans as Potential Agents in the Treatment of
  Neurodegenerative Disorders
• Etiological and Therapeutic Aspects in Neurodegenerative Disorders such as AD
• Tau, APoE Significance in AD, Oxidative Stress, Inflammation
• Clinical Aspects of AD & Minimal Cognitive Impariments (MCI)
• Tau & Mechanistic Aspects (I)
• Neuropathology & Tau (II)
• Neurogenetics of AD & PD; Genetic Basis for Responsiveness to Approved Drugs & Pharmacogenomics
• Pharmacoeconomics : Dementia & PD
• Biomarkers of Neurodegenerative Diseases
• Imaging in AD & PD
• Lewy Body Dementia (LBD): From Molecular Genetics to Animal Models and Treatment Strategies
• LBD, Triple Brain Amyloidosis, Multiple System Atrophy and Related Conditions
• AD: Animal Models
• Surgical, Stem Cells, Antisense and Gene Therapy in AD/PD
• Etiology & Pathogenesis of PD
• Clinical Evaluation & Treatment of PD
• Mechanism and Treatment of Motor Fluctuations in PD
• Dementia, Vascular Dementia in AD (I)
• Dementia, Vascular Dementia in AD (II)
• Prion Diseases and Conformational Diseases
• Oxidative Stress: Causes, Consequences and Interventions
• Inflammatory Processing in Neurodegeneration
• Model Systems to Explore Basic Biological Processes of Aging